All In MedTech

Device Trial Radar · NCT04248868

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

Recombinant tPA by Endovascular Administration for the Treatment of Submassive Pulmonary Embolism Using Pharmaco-mechanical Catheter Directed Thrombolysis for the redUction of Thrombus burdEn

Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

109

Actual

Start

Jun 23, 2020

Primary completion

Jun 22, 2022

Study completion Jun 23, 2022

Sponsor

Lead sponsor
Thrombolex, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jan 30, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.

Conditions

  • Pulmonary Embolism

Interventions

  • The Bashir™ Endovascular CatheterDevice

    The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.

  • r-tPADrug

    Pulse spray and infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: RV/LV Ratio DifferenceTime frame: 48 hours after the completion of r-tPA treatment
  2. Safety: Major BleedingTime frame: Within 72 hours of initiation of r-tPA administration

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • Miami Cardiac & Vascular Institute

    Miami, Florida

  • Advent Health Orlando

    Orlando, Florida

16 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.